Skip to main content
. 2022 Jul 6;6(13):3921–3931. doi: 10.1182/bloodadvances.2022007359

Figure 2.

Figure 2.

Overall survival and AML-free survival by Kaplan-Meier analysis of patients with OM-CMML, D-CMML, and P-CMML. (A) OS analysis. Patients with OM-CMML had a significantly longer OS than did those with D-CMML (median OS, 72.02 vs 50.37 months; P = .007) and P-CMML (median OS, 72.02 vs 24.12; P < .001). (B) LFS by Kaplan-Meier analysis of patients with OM-CMML, D-CMML, and P-CMML. Patients with OM-CMML had a significantly longer LFS than did those with D-CMML (median LFS, 72.02 vs 50.37 months; P = .008) and P-CMML (median LFS, 72.02 vs 23; P < .001). OS and LFS were compared with 2-sided log-rank tests.